INTRICON CORP Form 8-K February 21, 2017

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

**CURRENT REPORT** Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) February 17, 2017

## **INTRICON CORPORATION**

(Exact name of registrant as specified in its charter)

Pennsylvania1-500523-1069060(State or other jurisdiction of<br/>incorporation)(Commission File Number) (IRS Employer Identification No.)

## 1260 Red Fox Road, Arden Hills, MN 55112

(Address of principal executive offices) (Zip Code)

#### **Registrant's telephone number, including area code** (651) 636-9770

## Edgar Filing: INTRICON CORP - Form 8-K

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# Item 7.01 Regulation FD Disclosure.

On February 17, 2017, IntriCon Corporation completed the sale of the assets of its cardiac diagnostic monitoring business to Datrix, LLC. Terms of the transaction include a four year earn-out based on revenue thresholds.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## **INTRICON CORPORATION**

By: /s/ Scott Longval Name: Scott Longval Title: Chief Financial Officer Date: February 17, 2017